• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Study IDIncluded/excluded and reason for exclusion
Ackroyd 2000Only included low-grade dysplasia population
Bright 2007Only included non-dysplastic Barrett’s oesophagus
Dulai 2005Excluded high-grade dysplasia or CA population
Hage 2004Only included non-dysplastic Barrett’s oesophagus (32) and and low-grade dysplasia (8)
Luman 1996Only included non-dysplastic Barrett’s oesophagus
Mackenzie 2008Valid population but available only in abstract form and therefore not included in our review. The study compares 5-ALA versus porfimer sodium (summary available below*)
Overholt 2005–2007Included
Peters 1999Excluded high-grade dysplasia or CA population
Ragunath 2005Excluded by Guideline Development Group, for further information please refer to section 2.4.1 in the guideline
Shaheen 2008Included
Sharma 2006Excluded HGD or CA population
*

Study summary

Mackenzie (2008) randomised 32 patients, stratified per length of segment, to 5-ALA (n = 16) or porfimer sodium (n = 16). The authors stated that they used the standard protocol (no more details available) and 60 mg/kg 5-ALA, activated by 1178 J/cm of red laser light. Patients were then followed up with quadrantic biopsies every 2 cm at six weeks, four months and one year post-therapy.

  • Outcome: Eradication of high-grade dysplasia (HGD): 5-ALA 14/14 vs Photofrin 9/14: OR= 16.79 [0.83, 340.08]; p = NS
  • Outcome: Stricture: 5-ALA 1/16 vs Photofrin 6/16: OR= 0.12 [0.01, 1.09 ]; p = NS

Study summary

Mackenzie (2008) randomised 32 patients, stratified per length of segment, to 5-ALA (n = 16) or porfimer sodium (n = 16). The authors stated that they used the standard protocol (no more details available) and 60 mg/kg 5-ALA, activated by 1178 J/cm of red laser light. Patients were then followed up with quadrantic biopsies every 2 cm at six weeks, four months and one year post-therapy.

  • Outcome: Eradication of high-grade dysplasia (HGD): 5-ALA 14/14 vs Photofrin 9/14: OR= 16.79 [0.83, 340.08]; p = NS
  • Outcome: Stricture: 5-ALA 1/16 vs Photofrin 6/16: OR= 0.12 [0.01, 1.09 ]; p = NS

From: Appendix 5, Summary of relevant evidence from the Cochrane Review on Barrett’s Oesophagus (Rees, 2010)

Cover of Barrett’s Oesophagus
Barrett’s Oesophagus: Ablative Therapy for the Treatment of Barrett’s Oesophagus.
NICE Clinical Guidelines, No. 106.
Centre for Clinical Practice at NICE (UK).
Copyright © 2010, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.